0 Items
Select Page

Campylobacter

Campylobacter is the most common cause of food poisoning in both the UK and United States, with the great majority of cases occurring from infected poultry.

Our Campylobacter product range includes monoclonal antibodies for both for research applications and immunoassay development.

Campylobacter Background

The bacterial genus Campylobacter are non-spore forming, curved, gram-negative bacteria of the family Campylobacteriacae. Over twenty-five species of Campylobacter have been identified but approximately 90% of human disease is caused by Campylobacter jejuni. Infectious disease caused by pathogenic Campylobacter species is referred to as Campylobacteriosis. Other species of Campylobacter causing Campylobacteriosis include C. coli, C. lari and C. upsaliensis but cases are less frequently reported.

Birds, including poultry, are major reservoirs of C. jejuni, where the bacteria survive in the intestines and crop of healthy birds. Most reported outbreaks of Campylobacteriosis have been associated with the consumption of undercooked poultry or poultry products. Symptoms of infection generally include fever, abdominal cramps, watery or haemorrhagic diarrhoea and weight loss. Although the disease is self-limiting, complications may develop in some cases after infection, which include irritable bowel syndrome, Guillain Barre syndrome and other autoimmune neuropathies (CDC).

Campylobacter Antigens

The Native Antigen Company is pleased to offer a partially purified Campylobacter jejuni outer membrane protein, for diagnostic assay development and research purposes.

Campylobacter Antibodies

Our anti-Campylobacter jejuni monoclonal antibodies are specific for the detection of Campylobacter jejuni species and can be used as a pair in the development of immunoassays.

Our antibodies do not cross react with Helicobacter pylori, Escherichia coli, Salmonella enteriditis, Salmonella paratyphi, Salmonella typhi, Salmonella typhimurium, Shigella boydii, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Yersinia enterocolitica, Listeria monocytogenes or Staphylococcus aureus.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

A Q&A with David Flavell of Leukaemia Busters

In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research.Tell me about your scientific background David. I was born in a seaside town called Southport in...

Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine

In the second of a three-part series on COVID-19 vaccines, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.Rogue Responses Antibodies play a crucial role in...

The Bumpy Road to a Cytomegalovirus Vaccine

The development of a cytomegalovirus vaccine has been 50 years in the making. Are there any technologies in the pipeline that could prompt a breakthrough? This article was originally posted online at The Medicine Maker, a Texere publication.To say that...

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Gonorrhea: What’s Currently in the Clinical Pipeline?

This article was written by our friends at Infectious Diseases Hub, a free-to-access website that aims to deliver up-to-date, essential research and information on all aspects of microbiology, virology, mycology and parasitology – from bench to bedside....

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

6 + 3 =

Live Customer Feedback

Join our mailing list

* indicates required